Prevalence and incidence of anal human papillomavirus infection in Mexican men: Need for universal prevention policies

Autores/as

  • Hector Posso Universidad de la Sabana, Chia-Cundinamarca, Colombia.
  • Leith León-Maldonado Consejo Nacional de Ciencia y Tecnología (CONACYT)-Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
  • Betania Allen-Leigh Departamento de Métodos en Salud Pública, Dirección de Salud Reproductiva, Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
  • Jorge Salmerón Unidad Académica de Investigación Epidemiológica, Centro de Investigación en Políticas, Población y Salud, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.
  • Manuel Quiterio Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
  • Anna R Giuliano Center for Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Staci L Sudenga Center for Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Alan G Nyitray Department of Epidemiology, The University of Texas School of Public Health at Houston, Texas, USA.
  • B. Nelson Torres Center for Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Martha Abrahamsen Center for Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Eduardo Lazcano-Ponce Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.

DOI:

https://doi.org/10.21149/8454

Palabras clave:

human papilloma virus, prevalence, incidence, anal canal, men, apillomavirus vaccines

Resumen

Objective. Describe the natural history of anal HPV among men. Materials and methods. Prospective study among men 18-70 years (n=665), from Cuernavaca, Mexico who completed questionnaires and provided specimens (HPV genotyped) at enrollment and 1+ follow-up visit. HPV preva­lence and incidence were estimated. Prevalence ratios were calculated with Poisson regression using robust variance esti­mation. Person-time for incident HPV infection was estimated using number of events modeled as Poisson variable for total person-months. Results. Anal infection prevalence: any HPV type=15%, high-risk=8.4%, HPV16=1.4%, tetravalent vaccine types (4vHPV)=4.4%, nonavalent vaccine types (9vHPV)=6.3%. Factors associated with prevalence: 50+ lifetime female sex partners (adjusted prevalence ratio, a PR=3.25, 95% CI:1.12- 9.47), 10+ lifetime male sex partners (aPR=3.06, 95%CI:1.4- 6.68), and 1+ recent male anal sex partners (aPR=2.28, 95%CI:1.15-4.5). Anal incidence rate: high-risk HPV=7.8/1000 person-months (95%CI:6.0-10.1), HPV16=1.8/1000 person-months (95%CI:1.1-2.9),4vHPV=3.4/1000 person-months (95%CI:2.3-4.9) and 9vHPV=5.5/1000 person-months (95%CI:4.1-7.5). Conclusions. Implementation of universal HPV vaccination programs, including men, is a public health priority.

Descargas

Los datos de descargas todavía no están disponibles.

Descargas

Publicado

2018-12-13

Cómo citar

1.
Posso H, León-Maldonado L, Allen-Leigh B, Salmerón J, Quiterio M, Giuliano AR, Sudenga SL, Nyitray AG, Torres BN, Abrahamsen M, Lazcano-Ponce E. Prevalence and incidence of anal human papillomavirus infection in Mexican men: Need for universal prevention policies. Salud Publica Mex [Internet]. 13 de diciembre de 2018 [citado 5 de junio de 2024];60(6, nov-dic):645-52. Disponible en: https://saludpublica.mx/index.php/spm/article/view/8454

Artículos más leídos del mismo autor/a

1 2 3 4 5 6 7 8 9 10 > >>